ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Trading 3.1% Higher – Time to Buy?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) traded up 3.1% on Thursday . The company traded as high as $52.32 and last traded at $52.09. 15,949 shares changed hands during trading, a decline of 54% from the average session volume of 34,859 shares. The stock had previously closed at $50.52.

ALPS Medical Breakthroughs ETF Stock Performance

The stock has a 50 day simple moving average of $53.89 and a two-hundred day simple moving average of $51.86.

Institutional Investors Weigh In On ALPS Medical Breakthroughs ETF

Institutional investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 4th quarter valued at about $26,000. Comerica Bank acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 3rd quarter valued at about $27,000. Global Retirement Partners LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 4th quarter valued at about $34,000. Raymond James Financial Inc. acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 2nd quarter valued at about $82,000. Finally, Janney Montgomery Scott LLC acquired a new stake in shares of ALPS Medical Breakthroughs ETF during the 4th quarter valued at about $220,000.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.